424 related articles for article (PubMed ID: 20185635)
1. Suppressors of cytokine signaling abrogate diabetic nephropathy.
Ortiz-Muñoz G; Lopez-Parra V; Lopez-Franco O; Fernandez-Vizarra P; Mallavia B; Flores C; Sanz A; Blanco J; Mezzano S; Ortiz A; Egido J; Gomez-Guerrero C
J Am Soc Nephrol; 2010 May; 21(5):763-72. PubMed ID: 20185635
[TBL] [Abstract][Full Text] [Related]
2. Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis.
Ortiz-Muñoz G; Martin-Ventura JL; Hernandez-Vargas P; Mallavia B; Lopez-Parra V; Lopez-Franco O; Muñoz-Garcia B; Fernandez-Vizarra P; Ortega L; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):525-31. PubMed ID: 19164812
[TBL] [Abstract][Full Text] [Related]
3. Suppressor of cytokine signaling-1 ameliorates expression of MCP-1 in diabetic nephropathy.
Shi Y; Du C; Zhang Y; Ren Y; Hao J; Zhao S; Yao F; Duan H
Am J Nephrol; 2010; 31(5):380-8. PubMed ID: 20299783
[TBL] [Abstract][Full Text] [Related]
4. Suppressor of cytokine signaling (SOCS) 2 attenuates renal lesions in rats with diabetic nephropathy.
Zhou Y; Lv C; Wu C; Chen F; Shao Y; Wang Q
Acta Histochem; 2014 Jun; 116(5):981-8. PubMed ID: 24802166
[TBL] [Abstract][Full Text] [Related]
5. AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway.
Tsogbadrakh B; Ryu H; Ju KD; Lee J; Yun S; Yu KS; Kim HJ; Ahn C; Oh KH
Biochem Biophys Res Commun; 2019 Feb; 509(3):680-686. PubMed ID: 30616891
[TBL] [Abstract][Full Text] [Related]
6. A new pair of SOCS for diabetic nephropathy.
Brosius FC; Banes-Berceli A
J Am Soc Nephrol; 2010 May; 21(5):723-4. PubMed ID: 20413610
[No Abstract] [Full Text] [Related]
7. Evidence for the involvement of JAK/STAT/SOCS pathway in the mechanism of Tangshen formula-treated diabetic nephropathy.
Hu J; Fan X; Meng X; Wang Y; Liang Q; Luo G
Planta Med; 2014 Jun; 80(8-9):614-21. PubMed ID: 24853762
[TBL] [Abstract][Full Text] [Related]
8. Wogonin upregulates SOCS3 to alleviate the injury in Diabetic Nephropathy by inhibiting TLR4-mediated JAK/STAT/AIM2 signaling pathway.
Liu Y; Zhang M; Zeng L; Lai Y; Wu S; Su X
Mol Med; 2024 Jun; 30(1):78. PubMed ID: 38844873
[TBL] [Abstract][Full Text] [Related]
9. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.
Chen D; Liu Y; Chen J; Lin H; Guo H; Wu Y; Xu Y; Zhou Y; Zhou W; Lu R; Zhou J; Wu J
Eur J Pharmacol; 2021 Jul; 902():174121. PubMed ID: 33901462
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.
Recio C; Oguiza A; Lazaro I; Mallavia B; Egido J; Gomez-Guerrero C
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1953-60. PubMed ID: 25012131
[TBL] [Abstract][Full Text] [Related]
11. Japanese encephalitis virus infection modulates the expression of suppressors of cytokine signaling (SOCS) in macrophages: implications for the hosts' innate immune response.
Kundu K; Dutta K; Nazmi A; Basu A
Cell Immunol; 2013; 285(1-2):100-10. PubMed ID: 24140964
[TBL] [Abstract][Full Text] [Related]
12. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3.
Tamiya T; Kashiwagi I; Takahashi R; Yasukawa H; Yoshimura A
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):980-5. PubMed ID: 21508344
[TBL] [Abstract][Full Text] [Related]
13. miR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling.
Collins AS; McCoy CE; Lloyd AT; O'Farrelly C; Stevenson NJ
PLoS One; 2013; 8(7):e69090. PubMed ID: 23894411
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of suppressors of cytokine signaling in diabetic nephropathy.
Liu Q; Xing L; Wang L; Yao F; Liu S; Hao J; Liu W; Duan H
J Histochem Cytochem; 2014 Feb; 62(2):119-28. PubMed ID: 24217922
[TBL] [Abstract][Full Text] [Related]
15. SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition.
Lopez-Sanz L; Bernal S; Recio C; Lazaro I; Oguiza A; Melgar A; Jimenez-Castilla L; Egido J; Gomez-Guerrero C
Lab Invest; 2018 Oct; 98(10):1276-1290. PubMed ID: 29540859
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibition and progressive kidney disease.
Brosius FC; He JC
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):88-95. PubMed ID: 25415616
[TBL] [Abstract][Full Text] [Related]
17. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
18. Potential Natural Biomolecules Targeting JAK/STAT/SOCS Signaling in the Management of Atopic Dermatitis.
Kopalli SR; Annamneedi VP; Koppula S
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889539
[TBL] [Abstract][Full Text] [Related]
19. Functional conservation of suppressors of cytokine signaling proteins between teleosts and mammals: Atlantic salmon SOCS1 binds to JAK/STAT family members and suppresses type I and II IFN signaling.
Skjesol A; Liebe T; Iliev DB; Thomassen EI; Tollersrud LG; Sobhkhez M; Lindenskov Joensen L; Secombes CJ; Jørgensen JB
Dev Comp Immunol; 2014 Jul; 45(1):177-89. PubMed ID: 24582990
[TBL] [Abstract][Full Text] [Related]
20. Expression of JAKs/STATs pathway molecules in rat model of rapid focal segmental glomerulosclerosis.
Liang Y; Jin Y; Li Y
Pediatr Nephrol; 2009 Sep; 24(9):1661-71. PubMed ID: 19350281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
